<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5859">
  <stage>Registered</stage>
  <submitdate>28/04/2016</submitdate>
  <approvaldate>28/04/2016</approvaldate>
  <nctid>NCT02755857</nctid>
  <trial_identification>
    <studytitle>Bioavailability Study of Lozanoc 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis</studytitle>
    <scientifictitle>A Single-arm, Multiple-Dose, Steady-State, Bioavailability Study With Twice Daily Dosing of Lozanoc (65 mg Itraconazole Capsules, Mayne) Taken Regardless of Food</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MPG011</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neutropenia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Lozanoc

Experimental: Lozanoc - 65 mg, capsules, at least 2 capsules twice a day


Treatment: drugs: Lozanoc
65 mg

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Steady-state plasma itraconazole concentrations</outcome>
      <timepoint>3 weeks</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Provision of written, informed consent

          -  Age of at least 18 years

          -  No clinical evidence of active systemic fungal infection

          -  Physician-recommended continuation of oral itraconazole as primary prophylaxis in
             patients at risk of systemic fungal infections or otherwise requiring a long-term
             itraconazole maintenance regimen, including patients:

               -  who have had or are about to have a heart, lung or bone marrow transplant

               -  on combination chemotherapy for cancer

               -  with an aspergilloma, chronic pulmonary aspergillus bronchitis, or allergic
                  bronchopulmonary aspergillosis

          -  At least 21 days of prior dosing with oral itraconazole, either Lozanoc 50mg capsules
             twice daily or Sporanox 100mg capsules twice daily.

          -  Body mass index between 15.0 and 35.0 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant, planning pregnancy or breastfeeding

          -  Plasma itraconazole concentration greater than 1500ng/mL (in patients on Lozanoc 50mg
             capsules)

          -  Congestive cardiac failure or other causes of ventricular dysfunction that may
             outweigh the benefit of itraconazole

          -  Hypersensitivity to Lozanoc or to any of its excipients

          -  Coadministration of the following drugs:

               -  CYP3A4 metabolised substrates that can prolong the QT-interval: sertindole,
                  terfenadine

               -  CYP3A4 metabolised 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase
                  inhibitors: simvastatin, lovastatin

               -  Potent CYP3A4 inhibitor: dronedarone

               -  Triazolam, alprazolam and oral midazolam

               -  Ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine) and
                  ergotamine</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/07/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St Vincent's Hospital - Darlinghurst</hospital>
    <postcode>2010 - Darlinghurst</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Mayne Pharma International Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This open-labelled, single arm study is a follow-on from Study MPG010 to compare the relative
      bioavailability of Lozanoc 65 mg Capsules against Lozanoc 50 mg Capsules and Sporanox 100 mg
      Capsules in patients requiring itraconazole anti-fungal prophylaxis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02755857</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Deborah Marriott, MBBS BSc(MED) FRACP FRCPA</name>
      <address>St. Vincent's Medical Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Stuart J Mudge, PhD</name>
      <address />
      <phone>+61386147704</phone>
      <fax />
      <email>stuart.mudge@maynepharma.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>